Association of polymorphisms in the beta-2 adrenergic receptor gene with fracture risk and bone mineral density

详细信息    查看全文

• 作者：A. G. Veldhuis-Vlug ; L. Oei ; P. C. Souverein ; M. W. T. Tanck…
• 关键词：Beta ; 2 adrenergic receptor ; Bone mineral density ; Bone–brain–nervous system interactions ; Fracture ; Human association studies ; Polymorphisms
• 刊名：Osteoporosis International
• 出版年：2015
• 出版时间：July 2015
• 年：2015
• 卷：26
• 期：7
• 页码：2019-2027
• 全文大小：527 KB
• 参考文献：1.Kajimura D, Hinoi E, Ferron M, Kode A, Riley KJ, Zhou B, Guo XE, Karsenty G (2011) Genetic determination of the cellular basis of the sympathetic regulation of bone mass accrual. J Exp Med
  2.Toulis KA, Hemming K, Stergianos S, Nirantharakumar K, Bilezikian JP (2013) +|-Adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender, and site-specific effects. Osteoporos Int 1-
  3.Rosenbaum DM, Rasmussen SGF, Kobilka BK (2009) The structure and function of G-protein-coupled receptors. Nature 459:356-3PubMed Central PubMed View Article
  4.Reihsaus E, Innis M, MacIntyre N, Liggett SB (1993) Mutations in the gene encoding for the +|2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 8:334-9PubMed View Article
  5.Panebra A, Wang WC, Malone MM, Pitter DR, Weiss ST, Hawkins GA, Liggett SB (2010) Common ADRB2 haplotypes derived from 26 polymorphic sites direct beta2-adrenergic receptor expression and regulation phenotypes. PLoS One 5:e11819PubMed Central PubMed View Article
  6.Liggett SB (2000) Pharmacogenetics of beta-1- and beta-2-adrenergic receptors. Pharmacology 61:167-3PubMed View Article
  7.Green SA, Cole G, Jacinto M, Innis M, Liggett SB (1993) A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 268:23116-1PubMed
  8.Green SA, Turki J, Innis M, Liggett SB (1994) Amino-terminal polymorphisms of the human. beta 2-Adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33:9414-9PubMed View Article
  9.Turki J, Lorenz JN, Green SA, Donnelly ET, Jacinto M, Liggett SB (1996) Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci 93:10483-8PubMed Central PubMed View Article
  10.Small KM, McGraw DW, Liggett SB (2003) Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 43:381-11PubMed View Article
  11.Ahles A, Engelhardt S (2009) Polymorphisms determine beta-adrenoceptor conformation: implications for cardiovascular disease and therapy. Trends Pharmacol Sci 30:188-3PubMed View Article
  12.Leineweber K, Heusch G (2009) Beta 1- and beta 2-adrenoceptor polymorphisms and cardiovascular diseases. Br J Pharmacol 158:61-9PubMed Central PubMed View Article
  13.Brodde OE (2008) Beta1- and beta2-adrenoceptor polymorphisms and cardiovascular diseases. Fundam Clin Pharmacol 22:107-5PubMed View Article
  14.Johnson JA, Liggett SB (2011) Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. Clin Pharmacol Ther 89:366-8PubMed Central PubMed View Article
  15.Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R (1997) Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 100:3184-8PubMed Central PubMed View Article
  16.Lipworth BJ, Basu K, Donald HP, Tavendale R, Macgregor DF, Ogston SA, Palmer CNA, Mukhopadhyay S (2013) Tailored second-line therapy in asthmatic children with the Arg16 genotype. Clin Sci 124:521-8PubMed View Article
  17.Large V, Hellstrom L, Reynisdottir S, Lonnqvist F, Eriksson P, Lannfelt L, Arner P (1997) Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. J Clin Invest 100:3005-3PubMed Central PubMed View Article
  18.Kulminski AM, Culminskaya I, Ukraintseva SV, Arbeev KG, Land KC, Yashin AI (2010) Beta2-adrenergic receptor gene polymorphisms as systemic determinants of healthy aging in an evolutionary context. Mech Ageing Dev 131:338-5PubMed Central PubMed View Article
  19.Adriani KS, Brouwer MC, Baas F, Zwinderman AH, van der Ende A, van de Beek D (2012) Genetic variation in the +|2-adrenocepter gene is associated with susceptibility to bacterial meningitis in adults. PLoS ONE 7:e37618PubMed Central PubMed View Article
  20.Chu X, Dong Y, Shen M, Sun L, Dong C, Wang Y, Wang B, Zhang K, Hua Q, Xu S, Huang W (2009) Polymorphisms in the ADRB2 gene and Graves disease: a case–control study and a meta-analysis of available evidence. BMC Med Genet 10:26PubMed Central PubMed View Article
  21.Wieren-de Wijer D, Maitland-van der Zee A-H, Boer A, Stricker B, Kroon A, Leeuw P, Bozkurt O, Klungel O (2009) Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment. Pharm World Sci 31:158-4PubMed View Article
  22.van Wieren-de Wijer DB, Maitland-van der Zee A-H, de Boer A, Kroon AA, de Leeuw PW, Schiffers P, Janssen RG, Psaty BM, van Duijn CM, Stricker BH, Klungel OH (2009) Interaction between the Gly460Trp +|-adducin gene variant and diuretics on the risk of myocardial infarction. J H
• 作者单位：A. G. Veldhuis-Vlug (1)
  L. Oei (2) (3) (4)
  P. C. Souverein (5)
  M. W. T. Tanck (6)
  F. Rivadeneira (2) (3) (4)
  M. C. Zillikens (2) (4)
  P. W. Kamphuisen (7)
  A.H. Maitland - van der Zee (5)
  M. C. H. de Groot (5)
  A. Hofman (3) (4)
  A. G. Uitterlinden (2) (3) (4)
  E. Fliers (1)
  A. de Boer (5)
  P. H. Bisschop (1)
  
  1. Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands
  2. Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
  3. Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands
  4. Netherlands Genomics Initiative (NGI)-sponsored Netherlands Consortium of Healthy Aging (NCHA), Leiden, The Netherlands
  5. Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
  6. Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
  7. Department of Vascular Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Orthopedics
  Gynecology
  Endocrinology
  Rheumatology
  
• 出版者：Springer London
• ISSN：1433-2965

文摘

Summary Signaling through the beta-2 adrenergic receptor (B2AR) on the osteoblast influences bone remodeling in rodents. In the B2AR gene, three polymorphisms influence receptor function. We show that these polymorphisms are not associated with fracture risk or bone mineral density in the UCP, Rotterdam Study, and GEFOS cohorts. Introduction Signaling through the beta-2 adrenergic receptor (B2AR) on the osteoblast influences bone remodeling in rodents. In the B2AR gene, three polymorphisms are known to influence receptor function in vitro and in vivo (rs1042713, rs1042714, and rs1800888). We examined the role of these polymorphisms in the B2AR gene on human bone metabolism. Methods We performed nested case–control studies to determine the association of these polymorphisms with fracture risk in the Utrecht Cardiovascular Pharmacogenetics (UCP) cohort and in three cohorts of the Rotterdam Study. We also determined the association of these polymorphisms with bone mineral density (BMD) in the GEFOS Consortium. UCP contains drug-dispensing histories from community pharmacies linked to national registrations of hospital discharges in the Netherlands. The Rotterdam Study is a prospective cohort study investigating demographics and risk factors of chronic diseases. GEFOS is a large international collaboration studying the genetics of osteoporosis. Fractures were defined by ICD-9 codes 800-29 in the UCP cohort (158 cases and 2617 unmatched controls) and by regular X-ray examinations, general practitioner, and hospital records in the Rotterdam Study (2209 cases and 8559 unmatched controls). BMD was measured at the femoral neck and lumbar spine using dual-energy X-ray absorptiometry in GEFOS (N--2,961). Results Meta-analysis of the two nested case–control studies showed pooled odds ratios of 0.98 (0.91-.05, p--.52), 1.04 (0.97-.12, p--.28), and 1.16 (0.83-.62, p--.38) for the associations between rs1042713, rs1042714, and rs1800888 per minor allele and fractures, respectively. There were no significant associations of the polymorphisms and BMD in GEFOS. Conclusion In conclusion, polymorphisms in the beta-2 adrenergic receptor gene are not associated with fracture risk or BMD.